BlackRock, Inc. Increases Stake in LENZ Therapeutics, Inc.

BlackRock, Inc. has filed a Schedule 13G with the SEC, disclosing an increased ownership stake in LENZ Therapeutics, Inc. As of September 30, 2025, BlackRock beneficially owns 1,442,864 shares of LENZ Therapeutics' common stock, representing a 5.1% ownership stake. This marks an increase of 10,403 shares from their previous holdings, with the value of their stake rising by $16,378,408.80, a 39.01% increase. The filing indicates that BlackRock acquired these shares in the ordinary course of business and not with the intent to influence control of LENZ Therapeutics. The filing also includes certifications and exhibits, such as a Power of Attorney and details on subsidiary identification.